Accustem Sciences Inc. (ACUT) stock
ACUTOTCPharmaceutical PreparationsFiscal year ends December 31
$0.15+0.00 (0.00%)
Close on Oct 16, 2026Market cap $2.37MP/E –Yield –
Accustem Sciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Accustem Sciences's operating income for the twelve months ending Jun 30, 2026 was -$1.65M. For fiscal 2025 it was -$1.76M. The highest annual figure on record is -$670.61K in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.76M | – |
| FY2024 | Dec 31, 2024 | -$1.51M | – |
| FY2023 | Dec 31, 2023 | -$2.05M | – |
| FY2022 | Dec 31, 2022 | -$3.75M | – |
| FY2021 | Dec 31, 2021 | -$670.61K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$252.57K | – |
| Q1 FY2026 | Mar 31, 2026 | -$485.88K | – |
| Q4 FY2025 | Dec 31, 2025 | -$514.39K | – |
| Q3 FY2025 | Sep 30, 2025 | -$399.90K | – |
| Q2 FY2025 | Jun 30, 2025 | -$401.40K | – |
| Q1 FY2025 | Mar 31, 2025 | -$440.41K | – |
| Q4 FY2024 | Dec 31, 2024 | -$372.10K | – |
| Q3 FY2024 | Sep 30, 2024 | -$328.17K | – |
| Q2 FY2024 | Jun 30, 2024 | -$278.23K | – |
| Q1 FY2024 | Mar 31, 2024 | -$526.60K | – |
| Q4 FY2023 | Dec 31, 2023 | -$246.04K | – |
| Q3 FY2023 | Sep 30, 2023 | -$598.53K | – |
| Q2 FY2023 | Jun 30, 2023 | -$372.76K | – |
| Q1 FY2023 | Mar 31, 2023 | -$833.34K | – |
| Q4 FY2022 | Dec 31, 2022 | -$978.53K | – |
| Q3 FY2022 | Sep 30, 2022 | -$899.13K | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.08M | – |
| Q1 FY2022 | Mar 31, 2022 | -$790.53K | – |
| Q4 FY2021 | Dec 31, 2021 | -$543.48K | – |
| Q3 FY2021 | Sep 30, 2021 | -$62.72K | – |
| Q2 FY2021 | Jun 30, 2021 | -$50.54K | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.87K | – |
See a number that looks wrong?